Selective alkylation/acylation of di- or trianions: Expeditious derivatization of endothelin antagonists

Synthetic Communications

Volumn 32, Issue 10, 2002, Pages 1615-1624

  Wu, Chengde ^a   Blok, Natalie ^a   Li, Wen ^a   Holland, George W ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

Endothelin; Endothelin antagonist; Selective acylation; Selective alkylation; Sitaxsentan

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; SITAXSENTAN; TBC 2576; UNCLASSIFIED DRUG;

ACYLATION; ALKYLATION; ANION TRANSPORT; ARTICLE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; LABORATORY DIAGNOSIS; PHOTOCHEMICAL QUENCHING; PRODUCT RECOVERY; PULMONARY HYPERTENSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0036268247     PISSN: 00397911     EISSN: None     Source Type: Journal    
DOI: 10.1081/SCC-120004154     Document Type: Article

References (7)

1. A conceptually new method of alkylating/acylating di- or trianions: Expeditious derivatization of endothelin receptor antagonists
2. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist
3. a selective endothelin antagonists
4. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
5. Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension (PAH)
6. A receptors